Human papilloma virus vaccines: Current scenario
暂无分享,去创建一个
[1] H. Jessen,et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.
[2] M. Lehtinen,et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[3] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.
[4] A. Moscicki,et al. Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old , 2010, Journal of acquired immune deficiency syndromes.
[5] R. Feldman,et al. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. , 2008, Vaccine.
[6] M. Forcier,et al. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention , 2010, Dermatologic therapy.
[7] S. Goldie,et al. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications , 2008, Reproductive health matters.
[8] G. Garnett,et al. The India HPV-vaccine suspension , 2010, The Lancet.
[9] L. Willmitzer,et al. Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants , 2003, Journal of Virology.
[10] D. Jenkins. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. , 2008, Gynecologic oncology.
[11] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[12] N. Khardori. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009 .
[13] L. Young,et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship , 2002, BJOG : an international journal of obstetrics and gynaecology.
[14] W. Poppe,et al. Why Consider Human Papillomavirus Vaccination in Older Women? , 2010, Gynecologic and Obstetric Investigation.
[15] C. Wheeler,et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.
[16] J. Palefsky,et al. Human papillomavirus-related disease in men: not just a women's issue. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[17] Beibei Lu,et al. Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis , 2011, BMC infectious diseases.
[18] P. Hsueh. Human papillomavirus, genital warts, and vaccines. , 2009, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[19] B. Das,et al. HPV vaccination : Issues in developing countries , 2009 .
[20] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[21] B. Hutton,et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials , 2007, Canadian Medical Association Journal.
[22] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[23] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[24] A. Forinash,et al. Safety of the HPV Bivalent and Quadrivalent Vaccines during Pregnancy , 2011, The Annals of pharmacotherapy.
[25] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[26] X. Castellsagué,et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. , 2008, Vaccine.
[27] P. Stern,et al. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. , 2006, Cancer research.
[28] R. Rose,et al. Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato , 2003, Journal of Virology.
[29] L. Segal,et al. Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. , 2011, Reproductive toxicology.
[30] K. Ault. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.
[31] G. Zimet,et al. Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Medicine. , 2006, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[32] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[33] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[34] D. Lowy,et al. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. , 2006, Vaccine.
[35] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[36] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.
[37] I. Carletti,et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years , 2009, Human vaccines.
[38] F. X. Bosch,et al. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.
[39] E. Sturgis,et al. Inaccurate assumptions about oropharyngeal cancer , 2009, BMJ : British Medical Journal.
[40] Christophe Fraser,et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. , 2007, Vaccine.
[41] S. Goldie,et al. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting , 2007, British Journal of Cancer.
[42] H. Keyserling,et al. Recommended Childhood and Adolescent Immunization Schedules—United States, 2011 , 2011, Pediatrics.
[43] A. Kasbe,et al. A comparative study to assess the knowledge and practicesregarding sexual health among the migrants and nonmigrantsin Mumbai city , 2011 .
[44] M. Stanley,et al. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer , 2007, British Journal of Cancer.
[45] L. Villa. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[46] Martha J. Brown,et al. Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions , 2007, Human vaccines.
[47] R. Rose,et al. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi , 2003, Archives of Virology.
[48] N. Kiviat,et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.
[49] K. McKeage,et al. AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®) , 2011, Drugs.
[50] J. Fortenberry,et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.
[51] M. Lehtinen,et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. , 2007, Vaccine.
[52] S. Franceschi,et al. Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.
[53] Bryn Nelson. A new front in the debate over HPV vaccines for boys , 2010, Cancer cytopathology.
[54] L. Mariani,et al. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future , 2010, Journal of Translational Medicine.
[55] J. Palefsky,et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. , 2010, The Journal of infectious diseases.